{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:18Z","timestamp":1787841498112,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01903-x","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T09:53:09Z","timestamp":1786096389000},"page":"1214-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Crossing the milestone: landmark-based conditional survival after first-line CDK4\/6 inhibitor therapy in HR+\/HER2\u2212metastatic breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-0373","authenticated-orcid":false,"given":"Tu\u011fba","family":"\u00d6nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0182-3933","authenticated-orcid":false,"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"1","key":"1903_CR1","doi-asserted-by":"publisher","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open Jan. 2025;10(1):104103. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104103.","journal-title":"ESMO Open Jan"},{"key":"1903_CR2","doi-asserted-by":"publisher","unstructured":"Piezzo M, Chiodini P, Riemma M, et al. Progression-Free Survival and Overall Survival of CDK 4\/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci Sep. 2020;3(17). https:\/\/doi.org\/10.3390\/ijms21176400.","DOI":"10.3390\/ijms21176400"},{"key":"1903_CR3","doi-asserted-by":"publisher","unstructured":"Patel R, Mathews J, Hamm C, et al. Real-World Experience with CDK4\/6 Inhibitors in the First-Line Palliative Setting for HR+\/HER2- Advanced Breast Cancer. Curr Oncol Jan. 2025;20(1). https:\/\/doi.org\/10.3390\/curroncol32010052.","DOI":"10.3390\/curroncol32010052"},{"issue":"15","key":"1903_CR4","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1200\/JCO.2009.25.9697","volume":"20","author":"ML Janssen-Heijnen","year":"2010","unstructured":"Janssen-Heijnen ML, Gondos A, Bray F, et al. Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol May. 2010;20(15):2520\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.25.9697.","journal-title":"J Clin Oncol May"},{"key":"1903_CR5","doi-asserted-by":"publisher","first-page":"800813","DOI":"10.3389\/fonc.2022.800813","volume":"12","author":"M Xiao","year":"2022","unstructured":"Xiao M, Zhang P. Conditional cause-specific survival after chemotherapy and local treatment for primary stage IV breast cancer: A population-based study. Front Oncol. 2022;12:800813. https:\/\/doi.org\/10.3389\/fonc.2022.800813.","journal-title":"Front Oncol"},{"issue":"3","key":"1903_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-020-06040-3","volume":"186","author":"M Moossdorff","year":"2021","unstructured":"Moossdorff M, Vane MLG, van Nijnatten TJA, et al. Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer. Breast Cancer Res Treat Apr. 2021;186(3):863\u201370. https:\/\/doi.org\/10.1007\/s10549-020-06040-3.","journal-title":"Breast Cancer Res Treat Apr"},{"issue":"7","key":"1903_CR7","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1158\/1078-0432.CCR-14-2154","volume":"1","author":"S Hieke","year":"2015","unstructured":"Hieke S, Kleber M, Konig C, Engelhardt M, Schumacher M. Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. Clin Cancer Res Apr. 2015;1(7):1530\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2154.","journal-title":"Clin Cancer Res Apr"},{"issue":"20","key":"1903_CR8","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1002\/cncr.28273","volume":"15","author":"EC Zabor","year":"2013","unstructured":"Zabor EC, Gonen M, Chapman PB, Panageas KS. Dynamic prognostication using conditional survival estimates. Cancer Oct. 2013;15(20):3589\u201392. https:\/\/doi.org\/10.1002\/cncr.28273.","journal-title":"Cancer Oct"},{"key":"1903_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejca.2018.07.124","volume":"102","author":"MC van Maaren","year":"2018","unstructured":"van Maaren MC, Strobbe LJA, Smidt ML, Moossdorff M, Poortmans PMP, Siesling S. Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years. Eur J Cancer Oct. 2018;102:82\u201394. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.124.","journal-title":"Eur J Cancer Oct"},{"key":"1903_CR10","doi-asserted-by":"publisher","unstructured":"Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. J Natl Cancer Inst Sep. 2015;107(9). https:\/\/doi.org\/10.1093\/jnci\/djv156.","DOI":"10.1093\/jnci\/djv156"},{"issue":"26","key":"1903_CR11","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1002\/sim.7019","volume":"20","author":"X Mi","year":"2016","unstructured":"Mi X, Hammill BG, Curtis LH, Lai EC, Setoguchi S. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med Nov. 2016;20(26):4824\u201336. https:\/\/doi.org\/10.1002\/sim.7019.","journal-title":"Stat Med Nov"},{"key":"1903_CR12","doi-asserted-by":"publisher","first-page":"104597","DOI":"10.1016\/j.breast.2025.104597","volume":"84","author":"CH Lee","year":"2025","unstructured":"Lee CH, Chen PH, Jhou HJ, et al. Real-world comparative effectiveness of first-line abemaciclib versus palbociclib in HR+\/HER2- metastatic breast cancer: A propensity-matched retrospective analysis. Breast Dec. 2025;84:104597. https:\/\/doi.org\/10.1016\/j.breast.2025.104597.","journal-title":"Breast Dec"},{"key":"1903_CR13","doi-asserted-by":"publisher","unstructured":"Miron AI, Anghel AV, Barnonschi AA, et al. Real-World Outcomes of CDK4\/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania. Diagnostics (Basel) Jun. 2023;1(11). https:\/\/doi.org\/10.3390\/diagnostics13111938.","DOI":"10.3390\/diagnostics13111938"},{"issue":"9","key":"1903_CR14","doi-asserted-by":"publisher","first-page":"105570","DOI":"10.1016\/j.esmoop.2025.105570","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, et al. Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open Sep. 2025;10(9):105570. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105570.","journal-title":"ESMO Open Sep"},{"issue":"3","key":"1903_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/fon-2021-0716","volume":"18","author":"K Mycock","year":"2022","unstructured":"Mycock K, Zhan L, Hart K, et al. Real-world treatment of patients with palbociclib for HR+\/HER2-advanced\/metastatic breast cancer: the Europe IRIS study. Future Oncol Jan. 2022;18(3):349\u201362. https:\/\/doi.org\/10.2217\/fon-2021-0716.","journal-title":"Future Oncol Jan"},{"key":"1903_CR16","doi-asserted-by":"publisher","first-page":"JGO1800239","DOI":"10.1200\/JGO.18.00239","volume":"5","author":"J Waller","year":"2019","unstructured":"Waller J, Mitra D, Mycock K, et al. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. J Glob Oncol May. 2019;5:JGO1800239. https:\/\/doi.org\/10.1200\/JGO.18.00239.","journal-title":"J Glob Oncol May"},{"key":"1903_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2018.10.009","volume":"43","author":"G Taylor-Stokes","year":"2019","unstructured":"Taylor-Stokes G, Mitra D, Waller J, Gibson K, Milligan G, Iyer S. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+\/HER2-negative advanced\/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Breast Feb. 2019;43:22\u20137. https:\/\/doi.org\/10.1016\/j.breast.2018.10.009.","journal-title":"Breast Feb"},{"issue":"6","key":"1903_CR18","doi-asserted-by":"publisher","first-page":"105105","DOI":"10.1016\/j.esmoop.2025.105105","volume":"10","author":"T Decker","year":"2025","unstructured":"Decker T, Brucker C, Engel A, et al. Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study. ESMO Open Jun. 2025;10(6):105105. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105105.","journal-title":"ESMO Open Jun"},{"issue":"17","key":"1903_CR19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"10","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol Jun. 2020;10(17):1951\u201362. https:\/\/doi.org\/10.1200\/JCO.19.02488.","journal-title":"J Clin Oncol Jun"},{"issue":"12","key":"1903_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol Dec. 2020;31(12):1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol Dec"},{"key":"1903_CR21","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017."},{"issue":"3","key":"1903_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-019-05262-4","volume":"176","author":"MP Lux","year":"2019","unstructured":"Lux MP, Bohme S, Hucherig S, Jeratsch U, Kurschner N, Luftner D. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res Treat Aug. 2019;176(3):495\u2013506. https:\/\/doi.org\/10.1007\/s10549-019-05262-4.","journal-title":"Breast Cancer Res Treat Aug"},{"issue":"4","key":"1903_CR23","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121\u201331.","journal-title":"Am J Cancer Res"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01903-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:58:27Z","timestamp":1787839107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01903-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1903"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01903-x","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Ethics Committee of the Health Sciences University, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital. In accordance with national legislation and institutional policies, written informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}